Placebo matching to dupilumab
Sponsors
Regeneron Pharmaceuticals Inc., UZ Leuven
Conditions
AsthmaBullous PemphigoidEosinophilic gastritischronic rhinosinusitis with nasal polyps
Phase 2
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Gastritis with or without Eosinophilic Duodenitis
RecruitingCTIS2022-500795-62-00
Start: 2024-03-25Target: 19Updated: 2025-11-12
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid
CompletedCTIS2024-510745-34-00
Start: 2020-11-11End: 2024-12-10Target: 57Updated: 2024-09-04
Phase 4
A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSwNP
RecruitingCTIS2023-504014-30-00
Start: 2023-11-14Target: 44Updated: 2023-08-28
AIM4: Next Step – Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma
RecruitingCTIS2023-510458-18-00
Start: 2025-03-11Target: 62Updated: 2025-10-21